scholarly journals Is primary tumor location an independent prognostic factor in stage IV colon cancer?

2019 ◽  
Vol 3 (4) ◽  
pp. 196-202
Author(s):  
Sachio Yokoyama ◽  
Hideo Baba
Keyword(s):  
Colon Cancer ◽  
Prognostic Factor ◽  
Primary Tumor ◽  
Stage Iv ◽  
Tumor Location ◽  
Independent Prognostic Factor ◽  
Primary Tumor Location

Prognostic relevance of primary tumor location in stage III and II colon cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 703-703
Author(s):  
Arantzazu Martínez Barquín García ◽  
Olga Martinez Saez ◽  
Juan José Serrano Domingo ◽  
Roberto Martín Huertas ◽  
Maria Villamayor Delgado ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factor ◽  
Primary Tumor ◽  
Cox Model ◽  
Tumor Location ◽  
Stage Ii ◽  
Stage Iii ◽  
Primary Tumor Location ◽  
Risk Of Death ◽  
Prognostic Relevance

703 Background: Primary tumor location of colon cancer (CC) is emerging as an important prognostic factor owing to distinct biological features. However, this factor still does not represent a prognostic parameter when deciding for adyuvant or palliative chemotherapy. In a meta-analysis of 66 studies including patients with all stages of disease, left-sided primary tumor location was associated with a significantly reduced risk of death and this was independent of other prognostic factors. Methods: We retrospectively included patients with stage II and III CC that underwent surgical resection between 2009 and 2014 HURyC. We performed a multivariate Cox model analysis to estimate if tumor location is an independent prognostic factor for overall survival (OS). The model was further adjusted by including the following confounders: ECOG-PS, number of removed nodes ( < 12 or ≥ 12), perforation, grade, use of adyuvant chemotherapy and age. A covariate was considered a confounder factor if the difference between the adjusted and unadjusted coefficient of chemotherapy varied > 10%. Stata 13.1 was used to analyze the data. Results: 564 patients were identified (267 left sided and 297 right sided). The median follow-up of the entire cohort was 49 months. Globally, right sided CC was not significantly associated with better DFS or OS in comparison with left sided CC (HR: 0.74, p: 0.128; HR: 0.94, p: 0.75, respectively). By stages, stage II right sided CC seemed to show better DFS (HR: 0.45, p: 0.02), although no significant differences were found in OS (HR: 1.004, p: 0.98). Stage III right sided CC was not significantly associated with better DFS or OS in comparison with left sided CC (HR: 0.87, p: 0.585; HR: 0.66, p: 0.19, respectively). Conclusions: The multivariate analysis did not show significant differences in terms of prognostic relevance of primary tumor location in the adyuvant setting.

scholarly journals PD-0009 Primary Tumor Location is a Major Independent Prognostic Factor for Mcrc Patients

2012 ◽  
Vol 23 ◽  
pp. iv22
Author(s):  
Fotios Loupakis ◽  
Dongyun Yang ◽  
Shibao Feng ◽  
Chiara Cremolini ◽  
Wu Zhang ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Primary Tumor ◽  
Tumor Location ◽  
Independent Prognostic Factor ◽  
Primary Tumor Location

scholarly journals Impact of primary tumor location on patterns of recurrence and survival of patients undergoing resection of liver metastases from colon cancer

HPB ◽  
2020 ◽  
Vol 22 (1) ◽  
pp. 116-123 ◽  
Author(s):  
Nadia Russolillo ◽  
Elisa Sperti ◽  
Serena Langella ◽  
Francesca Menonna ◽  
Andrea Allieta ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Liver Metastases ◽  
Primary Tumor ◽  
Tumor Location ◽  
Primary Tumor Location ◽  
Patterns Of Recurrence

Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 683-683 ◽  
Author(s):  
Wen-zhuo He ◽  
Qiong Yang ◽  
Chang Jiang ◽  
Fang-xin Liao ◽  
Shou-sheng Liu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Colon Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Tumor Location ◽  
First Line ◽  
Primary Tumor Location ◽  
Colon Cancers

683 Background: There is currently no consensus about whether bevacizumab effectiveness is associated with the primary tumor location of metastatic colorectal cancer (mCRC). The aim of this study was to assess whether the primary tumor location was a predictor for bevacizumab treatment. Methods: From 2004 to 2013, 740 patients with mCRC treated with oxaliplatin / 5-FU / leucovorin (mFOLFOX6) or irinotecan / 5-FU / leucovorin (FOLFIRI) (CT group) and 244 patients treated with bevacizumab plus mFOLFOX6 or FOLFIRI (CT + B group) as first-line setting were included from Sun yat-sen university cancer center. Right-side colon cancers included those occurring in the cecum, ascending colon or transverse colon. Left-side colon cancers included those from descending or sigmoid colon. The primary outcome was overall survival (OS). Kaplan-Meier curves with log-rank tests were used to detect difference. All statistical tests were two sided. Results: 222 right-side colon, 259 left-side colon and 259 rectal cancer patients were included in CT group while 78 right-side colon, 86 left-side colon and 80 rectal cancer patients were included in CT + B group. Patients in CT + B group had similar OS compare with CT group only when the primary tumor located at right-side colon (median OS was 19.6 months for CT + B group versus 19.5 months for CT group, P = 0.269). For left-side colon cancer, significantly longer OS were observed in CT + B than CT group (22.3 months versus 21.9 months, P = 0.014). For rectal cancer patients, those in CT + B group also had longer OS than CT group (25.9 months versus 21.1 months, P = 0.005). Conclusions: Our data suggested that patients with right-side colon cancer could not get survival benefit from the addition of bevacizumab to first-line chemotherapy. Further data from randomized trials are needed to test our hypothesis. [Table: see text]

Clinical impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib or trifluridine/tipiracil as later-line.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 105-105
Author(s):  
Hiromichi Nakajima ◽  
Shota Fukuoka ◽  
Toshikazu Moriwaki ◽  
Toshiki Masuishi ◽  
Atsuo Takashima ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Prognostic Factor ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Primary Tumor ◽  
Univariate Analysis ◽  
Tumor Location ◽  
Primary Tumor Location ◽  
The Right ◽  
The Impact

105 Background: In the recent years, primary tumor location (PTL) is considered as an important prognostic and predictive factor in first-line treatment of mCRC. Although regorafenib (REG) and trifluridine/tipiracil (TFTD) have been available recently, the prognostic value of PTL in later-line with these agents is not well understood. TFTD improved survival regardless of PTL in the RECOURSE trial, while REG did not show survival benefit in the patients (pts) with rectal cancer in the CORRECT trial. Methods: We retrospectively evaluated pts with mCRC who were registered in a multicenter observational study (the REGOTAS study). The main inclusion criteria were ECOG PS of 0–2, refractory or intolerant to fluoropyrimidines, oxaliplatin, irinotecan, and anti-VEGF and anti-EGFR therapy (if KRAS wild type), and no prior use of REG and TFTD. The impact of PTL on overall survival (OS) were evaluated using Cox proportional hazards models based on baseline characteristics and propensity score matching. Results: A total of 550 pts (223 pts in the REG group, 327 pts in the TFTD group; 122 pts in the right-sided, 428 pts in the left-sided) were included in this study. Although the right-sided pts was significantly shorter OS compared with the left-sided pts by univariate analysis (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.63-0.99, P = 0.04), multivariate analysis revealed that PTL was not an independent prognostic factor (HR 0.88, 95% CI 0.69-1.1, P = 0.26). The similar results were obtained in each treatment group. In subgroup analysis according to PTL, OS were comparable between REG and TFTD groups regardless of PTL (HR 0.93, 95% CI 0.62-1.39 in the right-sided; HR 1.08, 95% CI 0.83-1.39 in the left-sided [excluding rectum]; and HR 1.01, 95% CI 0.62-1.62 in the rectal cancer pts). These results were similar in sensitivity analysis using propensity score-matching. Conclusions: In the present study, PTL is not a prognostic factor in patient with mCRC treated with either REG or TFTD as later-line. No difference in OS was observed between REG and TFTD groups irrespective of PTL.

Sign in / Sign up

Export Citation Format

Share Document